Page 2 - Tom Riga News Today

Spectrum Pharmaceuticals entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners, LLC (SLR) for a term loan facility of up to $65 million. The Company believes this transaction, combined with Spectrum's existing cash balance, provides sufficient capital to optimize the commercial launch of...

Most FDA panelists expressed doubts about the strength of evidence regarding the benefits of the experimental drug, especially given available therapies.

Spectrum Pharmaceuticals received regulatory approval for its oncology-related infection-reducing therapeutic, bolstering SPPI stock.

First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 yearsROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and proven safety and efficacy profileCommercial team ready to launch with product available in the fourth quarterBOSTON--(BUSINESS WIRE)--Spe...

SPPI earnings call for the period ending June 30, 2022.

SPPI earnings call for the period ending March 31, 2022.

Press release content from Business Wire. The AP news staff was not involved in its creation.

The FDA has accepted the resubmitted BLA for eflapegrastim to decrease the incidence of infection due to chemotherapy-induced neutropenia.

PALM BEACH, Fla., March 24, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The status of breast cancer as one of the most commonly occurring cancers in the world is expected to

SPPI earnings call for the period ending December 31, 2021.